0.509
price down icon10.80%   -0.0616
 
loading

Why is Bioxcel Therapeutics Inc (BTAI) Stock down?

We've noticed a 10.80% decline in Bioxcel Therapeutics Inc (BTAI) stock during the 2024-11-22 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
14 Nov, 2023:

BioXcel Therapeutics Stock (BTAI) dropped by 23.41% from $5.51 to $4.22 in the trading on Tuesday November 14, 2023. The reason why BTAI stock down today isnclude

  • Weak third-quarter results: The biopharmaceutical company posted a loss of $50.5 million, or $1.72 a share, compared with $41.8 million, or $1.49 a share, in the same quarter a year ago. Analysts had been expecting a loss of $1.27 a share. Revenue of $341,000 missed analyst projections for $600,000
  • Regulators' recommendation: BioXcel said that it is aligned with the U.S. Food and Drug Administration's recommendation for the Phase 3 trial of Igalmi as a treatment of agitation in bipolar disorders or schizophrenia to be conducted in the at-home setting.
14 Aug, 2023:

BioXcel Therapeutics (BTAI) stock is plummeting 41.5% from $7.40 to $4.33 Monday. BioXcel published its second-quarter results before the market opened this morning and paired the release with news of a major restructuring initiative.

https://www.fool.com/investing/2023/08/14/why-bioxcel-therapeutics-stock-is-getting-crushed/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

27 Jul, 2023:

BioXcel's stock price fell 7.94% from $10.33 to $9.51 on the news that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired the company's securities.

https://www.globenewswire.com/en/news-release/2023/07/26/2711219/32719/en/BioXcel-Therapeutics-Inc-Investors-Contact-Robbins-LLP-if-You-Incurred-Significant-Losses-in-BTAI.html

29 Jun, 2023:

BioXcel shares plummeted 63.8% from $17.67 to $6.39 after revealing a fraud investigation at its biggest study site.

https://www.investors.com/news/technology/btai-stock-ceo-vimal-mehta-says-this-alzheimers-news-is-a-huge-win-for-society/?src=A00220

25 May, 2023:

Shares of BioXcel Therapeutics (BTAI) were down 25.5% from $25.93 to $19.32 on Thursday after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 (dexmedetomidine) to treat acute agitation in bipolar disorders or schizophrenia.

https://www.fool.com/investing/2023/05/25/why-shares-of-bioxcel-therapeutics-are-dropping-th/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

14 Mar, 2023:

Shares of BioXcel Therapeutics (BTAI) declined 5.35% from $21.48 to $20.33 after announcing that it has confidentially submitted a draft registration statement relating to the proposed initial public offering of its common stock following its conversion into a corporation.

https://finance.yahoo.com/news/onkosxcel-therapeutics-announces-confidential-submission-201500018.html

10 Mar, 2023:

BioXcel shares plummeted 15.9% from $24.56 to $20.66 regarding the Q4 2022 Earnings Call.

https://finance.yahoo.com/news/q4-2022-bioxcel-therapeutics-inc-073220029.html

09 Mar, 2023:

BioXcel Therapeutics (BTAI) dipped 13.4% from $28.36 to $24.56 after issuing its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives.

https://finance.yahoo.com/news/bioxcel-therapeutics-reports-fourth-quarter-120000852.html

$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):